AUG 01, 2018
In this interview from ASRS 2018, Dr. Paul Hahn discusses highlights from this year’s Preferences and Trends (PAT) survey. Survey data shows that bevacizumab (Avastin) remains the top anti-VEGF drug, followed by aflibercept (Eyelea) and ranibizumab (Lucentis). Also of note is the decreasing use of scleral buckles and an increasing use of AMD home monitoring devices. The survey, which boasts a 40% response rate, showed that retina specialists are highly satisfied with their chosen subspecialty. The full survey results are available online to ASRS members.
Relevant Financial Disclosures: None